NCT00044213

Brief Summary

The purpose of this study is to determine the safety and effectiveness of ethylene diamine tetra-acetic (EDTA) chelation therapy in individuals with coronary artery disease.

Trial Health

90
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
1,708

participants targeted

Target at P75+ for phase_3 coronary-artery-disease

Timeline
Completed

Started Sep 2003

Longer than P75 for phase_3 coronary-artery-disease

Geographic Reach
2 countries

86 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 22, 2002

Completed
1 day until next milestone

First Posted

Study publicly available on registry

August 23, 2002

Completed
1 year until next milestone

Study Start

First participant enrolled

September 1, 2003

Completed
8.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2011

Completed
10 months until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2012

Completed
1.3 years until next milestone

Results Posted

Study results publicly available

November 5, 2013

Completed
Last Updated

November 5, 2013

Status Verified

August 1, 2013

Enrollment Period

8.1 years

First QC Date

August 22, 2002

Results QC Date

August 30, 2013

Last Update Submit

August 30, 2013

Conditions

Outcome Measures

Primary Outcomes (1)

  • A Composite of Total Mortality, Recurrent Myocardial Infarction, Stroke, Coronary Revascularization, and Hospitalization for Angina.

    Number of patients with events (composite of death from any cause, MI, stroke, coronary revascularization or hospitalization for angina) Events were centrally adjudicated where available; otherwise site reported events were used.

    Measured over a maximum 5-year follow-up period- 55 month median

Secondary Outcomes (1)

  • A Composite of Cardiovascular Death, Non-fatal Myocardial Infarction and Non-fatal Stroke.

    Measured over a maximum 5-year follow-up period- 55 month median

Study Arms (4)

EDTA + high dose vitamin

ACTIVE COMPARATOR

Participants will receive 40 infusions of active EDTA chelation and active high-dose oral vitamins.

Drug: EDTADietary Supplement: High Dose Vitamin

EDTA + high dose vitamin placebo

PLACEBO COMPARATOR

Participants will receive 40 infusions of EDTA chelation and placebo high-dose oral vitamins.

Drug: EDTADietary Supplement: High Dose Vitamin Placebo

EDTA placebo + high dose vitamin

PLACEBO COMPARATOR

Participants will receive 40 infusions of placebo EDTA chelation and active high-dose oral vitamins.

Drug: EDTA PlaceboDietary Supplement: High Dose Vitamin

EDTA placebo + high dose vitamin placebo

PLACEBO COMPARATOR

Participants will receive 40 infusions of placebo EDTA chelation and placebo high-dose oral vitamins.

Drug: EDTA PlaceboDietary Supplement: High Dose Vitamin Placebo

Interventions

EDTADRUG

Participants will receive 40 infusions of standard chelation solution.

EDTA + high dose vitaminEDTA + high dose vitamin placebo

Participants will receive 40 infusions of EDTA placebo.

EDTA placebo + high dose vitaminEDTA placebo + high dose vitamin placebo
High Dose VitaminDIETARY_SUPPLEMENT
EDTA + high dose vitaminEDTA placebo + high dose vitamin
High Dose Vitamin PlaceboDIETARY_SUPPLEMENT
EDTA + high dose vitamin placeboEDTA placebo + high dose vitamin placebo

Eligibility Criteria

Age50 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Heart attack at least 6 weeks prior to study start

You may not qualify if:

  • Serum creatinie level greater than 2.0 mg/dL
  • Platelet count less than 100,000/µL
  • Blood pressure greater than 160/100
  • Chelation therapy within 5 years prior to study start
  • History of allergic reactions to EDTA or any of the therapy's components
  • Coronary or carotid revascularization procedures within 6 months prior to study start or a scheduled revascularization
  • Cigarette smoking within 3 months prior to study start
  • Childbearing potential
  • History of liver disease
  • Active heart failure or heart failure hospitalization within 6 months.
  • Diagnoses of additional medical conditions that could otherwise limit patient survival
  • Inability to tolerate 500-mL infusions weekly.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (86)

Central Arkansas Veterans Healthcare System

Little Rock, Arkansas, 72205, United States

Location

University of Arkansas for Medical Sciences

Little Rock, Arkansas, 72205, United States

Location

Mt Holistic Health Center

Danville, California, 94526, United States

Location

Patrick A. Golden

Fresno, California, 93720, United States

Location

Scripps Center for Integrative Medicine

La Jolla, California, 92037, United States

Location

Phoenix Wellness Group

Napa, California, 94558, United States

Location

Aurora Denver Cardiology Associates

Denver, Colorado, 80218, United States

Location

The Blend Institute

Bradenton, Florida, 34221, United States

Location

Wellness Works

Brandon, Florida, 33510, United States

Location

Innovative Research of West Florida

Clearwater, Florida, 33756, United States

Location

Hyperbaric Medicine Inc.

Fort Walton Beach, Florida, 32547, United States

Location

White-Wilson Medical Center

Fort Walton Beach, Florida, 32547, United States

Location

Tru Med

Melbourne, Florida, 32901, United States

Location

Baptist Cardiac & Vascular Institute

Miami, Florida, 33176, United States

Location

Mount Sinai Medical Center

Miami Beach, Florida, 33140, United States

Location

Tri-Health Alternative Medical Center

Mt. Dora, Florida, 32757, United States

Location

Heart and Vascular Center for Research, Inc.

Sarasota, Florida, 34239, United States

Location

Florida Cardiovascular Institute

Tampa, Florida, 33609, United States

Location

Life Family Practice Center for Complementary and Alternative Medicine

The Villages, Florida, 32159, United States

Location

Florida Medical Clinic, P.A. Clinical Research Division

Zephyrhills, Florida, 33542, United States

Location

Emory University School of Medicine

Atlanta, Georgia, 30303, United States

Location

Full Circle Medical Center

Fort Oglethorpe, Georgia, 30742, United States

Location

Crossroads Healing Arts LLC

Goshen, Indiana, 46528, United States

Location

Integrative Medical Center at Schneck Medical Center

Seymour, Indiana, 47274, United States

Location

Northwest Indiana Cardiovascular Physicians Inc.

Valparaiso, Indiana, 46383, United States

Location

Kansas University Medical Center

Kansas City, Kansas, 66160, United States

Location

The Center for the Improvement of Functioning International

Wichita, Kansas, 67219, United States

Location

Complementary Medical Services

Mandeville, Louisiana, 70471, United States

Location

Maine Integrative Wellness

Portland, Maine, 04103, United States

Location

Johns Hopkins Bayview Medical Center

Baltimore, Maryland, 21224, United States

Location

Marino Center for Progressive Health

Cambridge, Massachusetts, 02140, United States

Location

Henry Ford Health System Preventative Cardiology Clay Ford Center for Athletic Medicine

Detroit, Michigan, 48202, United States

Location

The Preventive Medicine Center

Flint, Michigan, 48503, United States

Location

Born Preventive Health Care Clinic

Grand Rapids, Michigan, 49512, United States

Location

Parchment Family Practice

Kalamazoo, Michigan, 49004, United States

Location

Berman Center for Outcomes and Clinical Research

Minneapolis, Minnesota, 55404, United States

Location

Mayo Clinic and Foundation Cardiovascular Health Clinic

Rochester, Minnesota, 55905, United States

Location

University of Missouri Hospital and Clinics

Columbia, Missouri, 65201, United States

Location

Brian Dieterle, MD, PhD

Hollister, Missouri, 65673, United States

Location

Preventive Medicine

St Louis, Missouri, 63146, United States

Location

Deborah Heart and Lung Center

Browns Mills, New Jersey, 08015, United States

Location

Magaziner Center for Wellness

Cherry Hill, New Jersey, 08003, United States

Location

Park Professional Building

Roselle Park, New Jersey, 07204, United States

Location

Stockton Family Practice

Stockton, New Jersey, 08559, United States

Location

Heart Care Center

East Syracuse, New York, 13057, United States

Location

The Gables Natural Medicines Center & Day Spa Family Health Services

Mayville, New York, 14757, United States

Location

NYU School of Medicine

New York, New York, 10016, United States

Location

Rhinebeck Health Center

Rhinebeck, New York, 12572, United States

Location

Staten Island Heart

Staten Island, New York, 10305, United States

Location

Schachter Center for Complementary Medicine

Suffern, New York, 10901, United States

Location

Bronx-Lebanon Hospital Center

The Bronx, New York, 10457, United States

Location

Integrative Medical Associates, PLLC

Tryon, North Carolina, 28782, United States

Location

Celebration of Health Center

Bluffton, Ohio, 45817, United States

Location

University Hospitals of Cleveland

Cleveland, Ohio, 44106, United States

Location

The Ohio State University Medical Center

Columbus, Ohio, 43210, United States

Location

Comprehensive Heart Care, Inc.

Toledo, Ohio, 43606, United States

Location

Upper Valley Family Care

Troy, Ohio, 45373, United States

Location

COR Research

Oklahoma City, Oklahoma, 73103, United States

Location

St. Charles Health System

Bend, Oregon, 97701, United States

Location

Center for Environmental Medicine

Portland, Oregon, 97220, United States

Location

Wholistic Health Center

Greensburg, Pennsylvania, 15601, United States

Location

Woodlands Healing Research Center

Quakertown, Pennsylvania, 18951, United States

Location

Main Line Health Heart Center

Wynnewood, Pennsylvania, 19096, United States

Location

Biogenesis Medical Center

Landrum, South Carolina, 29356, United States

Location

Athens Surgery Clinic

Athens, Tennessee, 37303, United States

Location

The Castle Clinic, PLLC

Johnson City, Tennessee, 37601, United States

Location

Chelation Centers of Texas

Texas City, Texas, 77591, United States

Location

Freedom Center for Advanced Medicine

Provo, Utah, 84604, United States

Location

The Cardiovascular Group

Fairfax, Virginia, 22031, United States

Location

Virginia Beach General Hospital

Virginia Beach, Virginia, 23454, United States

Location

Hope Medical Holistic Clinic

Vancouver, Washington, 98663, United States

Location

Care Foundation Inc.

Wausau, Wisconsin, 54401, United States

Location

Waters Preventive Medical Center, LTD

Wisconsin Dells, Wisconsin, 53965, United States

Location

Cline Medical Centre

Nanaimo, British Columbia, V9R 2M9, Canada

Location

The Wellness Centre

Port Hawkesbury, Nova Scotia, V4P 1B5, Canada

Location

Chelation Center of Barrie, Inc.

Barrie, Ontario, L4N9T6, Canada

Location

Anti-Aging & Family Wellness Clinic

Madoc, Ontario, K0K 2K0, Canada

Location

Markham Integrative Medicine

Markham, Ontario, L3P 1Y8, Canada

Location

North Bay Complementary

North Bay, Ontario, P1B 4B8, Canada

Location

Seekers Centre for Integrative Medicine

Ottawa, Ontario, K2E 1B3, Canada

Location

Dr. C. Minielly

Smith Falls, Ontario, K7A 1C3, Canada

Location

Chelation Center of Don Valley Inc.

Toronto, Ontario, M3C3F2, Canada

Location

Jaconello Health Centre

Toronto, Ontario, M4K 3T1, Canada

Location

Chelation and Natural Therapy

Toronto, Ontario, M4W 3T1, Canada

Location

Chelox

Toronto, Ontario, M6H 3M2, Canada

Location

Saskatoon Chelation Centre

Saskatoon, Saskatchewan, S7M 5W1, Canada

Location

Related Publications (6)

  • Escolar E, Ujueta F, Kim H, Mark DB, Boineau R, Nahin RL, Goertz C, Lee KL, Anstrom KJ, Lamas GA. Possible differential benefits of edetate disodium in post-myocardial infarction patients with diabetes treated with different hypoglycemic strategies in the Trial to Assess Chelation Therapy (TACT). J Diabetes Complications. 2020 Aug;34(8):107616. doi: 10.1016/j.jdiacomp.2020.107616. Epub 2020 May 7.

  • Mark DB, Anstrom KJ, Clapp-Channing NE, Knight JD, Boineau R, Goertz C, Rozema TC, Liu DM, Nahin RL, Rosenberg Y, Drisko J, Lee KL, Lamas GA; TACT Investigators. Quality-of-life outcomes with a disodium EDTA chelation regimen for coronary disease: results from the trial to assess chelation therapy randomized trial. Circ Cardiovasc Qual Outcomes. 2014 Jul;7(4):508-16. doi: 10.1161/CIRCOUTCOMES.114.000977.

  • Lamas GA, Boineau R, Goertz C, Mark DB, Rosenberg Y, Stylianou M, Rozema T, Nahin RL, Lindblad L, Lewis EF, Drisko J, Lee KL; TACT (Trial to Assess Chelation Therapy) Investigators. Oral high-dose multivitamins and minerals after myocardial infarction: a randomized trial. Ann Intern Med. 2013 Dec 17;159(12):797-805. doi: 10.7326/0003-4819-159-12-201312170-00004.

  • Escolar E, Lamas GA, Mark DB, Boineau R, Goertz C, Rosenberg Y, Nahin RL, Ouyang P, Rozema T, Magaziner A, Nahas R, Lewis EF, Lindblad L, Lee KL. The effect of an EDTA-based chelation regimen on patients with diabetes mellitus and prior myocardial infarction in the Trial to Assess Chelation Therapy (TACT). Circ Cardiovasc Qual Outcomes. 2014 Jan;7(1):15-24. doi: 10.1161/CIRCOUTCOMES.113.000663. Epub 2013 Nov 19.

  • Lamas GA, Goertz C, Boineau R, Mark DB, Rozema T, Nahin RL, Lindblad L, Lewis EF, Drisko J, Lee KL; TACT Investigators. Effect of disodium EDTA chelation regimen on cardiovascular events in patients with previous myocardial infarction: the TACT randomized trial. JAMA. 2013 Mar 27;309(12):1241-50. doi: 10.1001/jama.2013.2107.

  • Lamas GA, Goertz C, Boineau R, Mark DB, Rozema T, Nahin RL, Drisko JA, Lee KL. Design of the Trial to Assess Chelation Therapy (TACT). Am Heart J. 2012 Jan;163(1):7-12. doi: 10.1016/j.ahj.2011.10.002.

MeSH Terms

Conditions

Coronary Artery Disease

Interventions

Edetic AcidVitamins

Condition Hierarchy (Ancestors)

Coronary DiseaseMyocardial IschemiaHeart DiseasesCardiovascular DiseasesArteriosclerosisArterial Occlusive DiseasesVascular Diseases

Intervention Hierarchy (Ancestors)

EthylenediaminesDiaminesPolyaminesAminesOrganic ChemicalsAcetatesAcids, AcyclicCarboxylic AcidsMicronutrientsPhysiological Effects of DrugsPharmacologic ActionsChemical Actions and UsesNutrientsFoodDiet, Food, and NutritionPhysiological PhenomenaFood and Beverages

Results Point of Contact

Title
Gervasio A. Lamas, M.D.
Organization
Mount Sinai Medical Center

Study Officials

  • Gervasio A Lamas, M.D.

    Icahn School of Medicine at Mount Sinai

    STUDY DIRECTOR

Publication Agreements

PI is Sponsor Employee
No
Restriction Type
OTHER
Restrictive Agreement
Yes

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
FACTORIAL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Chair, Department of Medicine- Chief, Division of Cardiology

Study Record Dates

First Submitted

August 22, 2002

First Posted

August 23, 2002

Study Start

September 1, 2003

Primary Completion

October 1, 2011

Study Completion

August 1, 2012

Last Updated

November 5, 2013

Results First Posted

November 5, 2013

Record last verified: 2013-08

Locations